Adenocarcinoma Survival Rate

Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial

The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach 43.6%.

MarketWatch · 2d

Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal cancer. The stock was up 12% to $9.73 in pre-market trading.

Business Insider · 2d

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37%

pancan2d

Research Spotlight – Pancreatic Cancer: A Look Back at 2024

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

Verywell Health on MSN1y

Types of Carcinoma

The Most Common Type of Cancer That Develops From Epithelial Cells Fact checked by Nick Blackmer A carcinoma is a type of ...

Endocrinology Advisor15d

AANHPI Adults With HCC Have Better Survival Rates Than White Adults

Asian American, Native Hawaiian, and Pacific Islander (AANHPI) patients with early-stage hepatocellular carcinoma (HCC) have significantly better survival outcomes compared with non-Hispanic White ...

Daily2d

Mixed histology protective factor impacting overall survival and progression free survival in Neuroendocrine Carcinoma of Cervix: Study

Neuroendocrine carcinoma of the cervix (NECC) , a rare type of cervical cancer, has a poor prognosis and is more aggressive ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results